AI assistant
CHIMERIC THERAPEUTICS LIMITED — Investor Presentation 2021
Jul 27, 2021
64648_rns_2021-07-27_209e17d8-ef14-43c7-ac49-fa73f4f19236.pdf
Investor Presentation
Open in viewerOpens in your device viewer
ASX Announcement
==> picture [262 x 53] intentionally omitted <==
July 28, 2021
CHIMERIC THERAPEUTICS CDH17 INVESTOR WEBINAR
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical-stage cell therapy company committed to bringing the promise of cell therapy to life for more patients, is pleased to announce it will hold an investor webinar regarding its exclusive licensing agreement with the University of Pennsylvania for the first CDH17 CAR T cell therapy.
The webinar will be held at 12:00pm (midday) AEST today, Wednesday 28 July.
Please register for the webinar at the following link: https://us02web.zoom.us/webinar/register/WN_6IXkAezyTY-h-HsUkmu8rw
Investors are invited to send questions prior to the webinar to [email protected]
After registering, you will receive a confirmation email containing information about joining the webinar. A recording will be made available shortly after the conclusion of the session, at the same link.
Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.
ABOUT CHIMERIC THERAPEUTICS
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression.
To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.
Chimeric Therapeutics is currently in a phase 1 clinical trial for our lead asset, CLTX CAR T. CLTX CAR T is a novel and promising CAR T therapy for the treatment of patients with Glioblastoma (GBM) developed by scientists at the City of Hope Medical Centre in California.
Chimeric Therapeutics is now actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.
LEVEL 3, 62 LYGON STREET CARLTON VIC 3053 AUSTRALIA
CHIMERIC THERAPEUTICS LIMITED | 1
==> picture [262 x 53] intentionally omitted <==
CONTACT
Investors
Jennifer Chow Chief Operating Officer Chimeric Therapeutics P: +9087238387
W: www.chimerictherapeutics.com
Media
Matthew Wright NWR Communications P: +61 451 896 420
LEVEL 3, 62 LYGON STREET CARLTON VIC 3053 AUSTRALIA
CHIMERIC THERAPEUTICS LIMITED | 2